Skip to main content

Advertisement

Table 1 Clinical data of patients

From: Novel application of multi-stimuli network inference to synovial fibroblasts of rheumatoid arthritis patients

Patient Gender/age Disease duration (years) RF ESR (mm/h) CRP (mg/ml) ARA Concurrent medication
EB87 F/65 12 + 50 106.7 5 NSAIDs
EB88 F/62 10 + 90 169.5 6 NSAIDs
EB213 F/69 15 + 94 99.1 4 NSAIDs, leflunomide, prednisone
EB220 F/57 20 + 23 2.3 4 NSAIDy, prednisone, MTX
EB221 F/66 12 + 7 5.4 4 NSAIDs, MTX
EB227 F/49 25 + 12 2.4 5 Celecoxib, prednisone, MTX, leflunomide
EB253 F/53 19 + 38 40.1 5 Azufildine
EB261 F/54 23 + 18 8.2 4 Prednisone, MTX, alendronate
EB266 F/63 11 + 35 17.4 5 NSAIDs, prednisone, azathioprin
EB268 F/53 8 + 25 14.8 6 NSAIDs, MTX, etanercept (TNF-blocker)
  1. ARA, number of American Rheumatism Association (now ACR) RA classification criteria; CRP, C-reactive protein (normal range < 5 mg/l); ESR, erythrocyte sedimentation rate; F, female; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs; RF, rheumatoid factor; +, positive.